Cargando…
Prostaglandin F2 alpha in benign and malignant breast tumours.
Prostaglandin F2 alpha (PGF2 alpha) was determined by radioimmunoassay in 57 breast carcinomata, 16 fibroadenomata, and 33 sclero-cystic-disease (SCD) specimens. In 41 cases of carcinoma and 10 cases of fibroadenoma, histologically non-malignant tissue was also obtained from the same breast. PGF2 al...
Autores principales: | Vergote, I. B., Laekeman, G. M., Keersmaekers, G. H., Uyttenbroeck, F. L., Vanderheyden, J. S., Albertyn, G. P., Haensch, C. F., De Roy, G. J., Herman, A. G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1985
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977075/ https://www.ncbi.nlm.nih.gov/pubmed/3859318 |
Ejemplares similares
-
Prostacyclin and thromboxane in benign and malignant breast tumours.
por: Laekeman, G. M., et al.
Publicado: (1986) -
Peripheral plasma immunoreactive 6-oxo-prostaglandin F1 alpha and gynaecological tumours.
por: Alam, M., et al.
Publicado: (1982) -
Multiexponential T2 relaxometry of benign and malignant adipocytic tumours
por: Nikiforaki, Katerina, et al.
Publicado: (2020) -
Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy.
por: van der Zee, A. G., et al.
Publicado: (1992) -
Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours
por: Hall, G H, et al.
Publicado: (2002)